Please assess the completion status of the following clinical trial:

Trial Title: Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent (IC)~* Age ≥ 40 years~* History of COPD for at least 12 months prior to enrollment (Visit V0)~* Chronic productive cough for 3 months in each of the 2 years prior to enrollment (if other causes of productive cough have been excluded) and/or an exacerbation with predominantly bronchitic symptoms at enrollment~* Presentation of an acute exacerbation of COPD that will be associated with increased sputum volume or change in sputum colour~* Documented fixed airway obstruction determined by an FEV1/FVC ratio (post-bronchodilator) \< 70% (if a pulmonary function test is not possible at Visit V0 a previous measurement can be taken which must not be older than 6 months)~* Former smoker (defined as: smoking cessation at least 1 year ago) or current smoker both with a smoking history of at least 10 pack years~Main Exclusion Criteria:~* Diagnosis of asthma and/or other relevant lung disease~* Known alpha-1-antitrypsin deficiency~* Recurrent exacerbations (within 8 weeks of a preceding exacerbation)~* Treatment of current exacerbation with oral corticosteroids and/or antibiotics already started at enrollment~* Treatment with PDE4 inhibitors within 3 months prior to Visit V0~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): added on to standard therapy for acute COPD exacerbations
- Placebo (Type: PLACEBO_COMPARATOR): added on to standard therapy for acute COPD exacerbations

Based on this trial design, predict the completion outcome and termination type (if applicable).